Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 16 to 30 of 39 results for endometriosis

  1. Heavy menstrual bleeding: assessment and management (NG88)

    This guideline covers assessing and managing heavy menstrual bleeding (menorrhagia). It aims to help healthcare professionals investigate the cause of heavy periods that are affecting a woman’s quality of life and to offer the right treatments, taking into account the woman’s priorities and preferences.

  2. Podcasts

    oral antibiotics and be cared for at home. Podcasts 27 May 2026 Endometriosis fertility care and gynaecological cancer guidance In this...

  3. News, blogs and podcasts

    to oral antibiotics and be cared for at home.Podcasts 27 May 2026 Endometriosis fertility care and gynaecological cancer guidance In...

  4. Pain management programmes:- Are pain management programmes a clinically and cost-effective intervention for women with endometriosis?

    programmes a clinically and cost-effective intervention for women with endometriosis? Any explanatory notes(if applicable) Why this is...

  5. NICE newsletters and alerts

    Subscribe to NICE newsletters and alerts for the latest healthcare guidance, clinical updates, and evidence-based resources across health and social care.

  6. Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain (NG193)

    This guideline covers assessing all chronic pain (chronic primary pain, chronic secondary pain, or both) and managing chronic primary pain in people aged 16 years and over. Chronic primary pain is pain with no clear underlying cause, or pain (or its impact) that is out of proportion to any observable injury or disease.

  7. Vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditions (HTG699)

    Evidence-based recommendations on vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditions. This involves removing the uterus (womb), and sometimes the fallopian tubes and ovaries, through the vagina.

  8. Endometriosis fertility care and gynaecological cancer guidance

    Home News Podcasts Endometriosis fertility care and gynaecological cancer guidance Podcasts 01 May 2026 Listen About this episode For the

  9. Endometriosis: diagnosis and management - surgical management - pain management post-surgery

    Discontinued Reference number: GID-NG10385

  10. Prioritisation board decisions 2025

    Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.

  11. Laparoscopic helium plasma coagulation of endometriosis (IPG54)

    This guidance has been updated and replaced by NICE interventional procedure guidance 171.

  12. Laparoscopic helium plasma coagulation for the treatment of endometriosis (IPG171)

    We have moved interventional procedures guidance 171 to become HealthTech guidance 112. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  13. One-piece closed bags for colostomies: late-stage assessment (HTG754)

    Late stage assessment (LSA) guidance on one-piece closed bags for colostomies

  14. Pelvic floor dysfunction: prevention and non-surgical management (NG210)

    This guideline covers the prevention, assessment and non-surgical management of pelvic floor dysfunction in women aged 12 and over. It aims to raise awareness and help women to reduce their risk of pelvic floor dysfunction. For women who have pelvic floor dysfunction, the guideline recommends interventions based on their specific symptoms.

  15. Ovarian cancer: identifying and managing familial and genetic risk (NG241)

    This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.